Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyforte Gold is an oral dietary supplement developed by Jainson Biotech for eye care. Formulated as softgel capsules, it contains a combination of omega-3 fatty acids (500 mg), lutein (10 mg), astaxanthin (2 mg), and zeaxanthin (2 mg). This combination of nutrients is designed to support visual development and protect against age-related eye disorders. Omega-3 fatty acids are essential for visual development and help reduce the risk of vascular and degenerative retinal diseases. Lutein and zeaxanthin are macular carotenoids that filter phototoxic blue light and provide antioxidant protection in the retina, helping to combat age-related macular degeneration, cataracts, and retinitis pigmentosa. Astaxanthin acts as a potent antioxidant, protecting retinal tissues from light-induced oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxyforte Gold.